Tekla Life Sciences Investors Share Price Nyse
Equities
US4040531000
Closed End Funds
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2021 | 2.29M 191M | Sales 2022 | 3.02M 252M | Capitalization | 343M 28.65B |
---|---|---|---|---|---|
Net income 2021 | 64M 5.34B | Net income 2022 | -105M -8.76B | EV / Sales 2021 | 225 x |
Net Debt 2021 | 10.04M 838M | Net Debt 2022 | 11.09M 925M | EV / Sales 2022 | 117 x |
P/E ratio 2021 |
7.95
x | P/E ratio 2022 |
-3.35
x | Employees | - |
Yield 2021 |
8.03% | Yield 2022 |
10.8% | Free-Float | 99.99% |
Managers | Title | Age | Since |
---|---|---|---|
Dan Omstead
PSD | President | 71 | 01/01/01 |
Jason Akus
CTO | Chief Tech/Sci/R&D Officer | - | - |
Laura Woodward
CMP | Compliance Officer | 56 | 01/09/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 01/07/01 | |
Dan Omstead
PSD | President | 71 | 01/01/01 |
Jeffrey Bailey
BRD | Director/Board Member | 62 | 01/20/01 |
1st Jan change | Capi. | |
---|---|---|
+3.17% | 12.63B | |
+6.03% | 9.1B | |
-4.46% | 5.38B | |
+5.56% | 5.36B | |
+5.68% | 5.19B | |
+10.33% | 4.47B | |
+14.70% | 4.44B | |
+1.29% | 4B | |
+3.58% | 3.86B |